10/07/2025 06:30
EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Study br/ Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206... Lire...
01/07/2025 13:15
EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Alliance/Market Launch br/ Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ ranibizumab across SubSaharan Africa... Lire...
27/06/2025 15:51
EQS-News: Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Issue of Debt/Bond br/ Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and... Lire...
27/06/2025 15:45
EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd pEQSAdhoc: Formycon AG / Key words: Issue of Debt/Bondbr/ Formycon successfully places an EUR 70 million senior unsecured floating rate bond br/br/ 27Jun2025 / 15:45 CET/CESTbr/ Disclosure of an inside... Lire...
26/06/2025 06:30
EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Miscellaneous br/ Teva becomes secondary commercialization partner for Formycons Stelara® biosimilar FYB202 ustekinumab under the brand name... Lire...
25/06/2025 06:30
EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Miscellaneous br/ U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar... Lire...
24/06/2025 19:50
EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Issue of Debt/Bond br/ Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period br/br/ 24.06.2025 / 19:50... Lire...
20/06/2025 09:00
EQS-News: Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Issue of Debt/Bond br/ Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse br/br/ 20.06.2025 / 09:00... Lire...
18/06/2025 16:43
EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: AGM/EGM/Miscellaneous br/ Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities br/br/ 18.06.2025... Lire...